论文部分内容阅读
目的研究脓毒血症合并感染性休克患者应用血必净联合乌司他丁治疗的临床价值分析。方法选取我院从2013年6月至2014年7月收治的脓毒血症合并感染性休克患者100例,采用随机数字表法将100例脓毒血症合并感染性休克患者分为观察组(50例)和对照组(50例);对照组采取常规方法进行治疗,观察组采取血必净联合乌司他丁进行治疗,观察对比两组患者的临床疗效、APACHEⅡ评分以及炎症因子的情况。结果观察组的有效率为96.00%,对照组的有效率为82.00%,观察组的有效率明显高于对照组,差异具有统计学意义(P<0.05);观察组的APACHEⅡ评分明显低于对照组,差异具有统计学意义(P<0.05);观察组的炎症因子IL-6、TNF-a、PCT均优于对照组,差异具有统计学意义(P<0.05)。结论乌司他丁联合血必净治疗脓毒血症合并感染性休克具有明显的临床效果,且减低患者的APACHEⅡ评分,调节体内的炎症因子,减轻患者痛苦,因此值得在临床上进一步推广应用。
Objective To study the clinical value of Xuebijing combined with ulinastatin in patients with sepsis and septic shock. Methods One hundred patients with septic shock and septic shock were selected from June 2013 to July 2014 in our hospital. 100 patients with sepsis and septic shock were randomly divided into observation group 50 cases) and control group (50 cases). The control group was treated by conventional method. The observation group was treated with Xuebijing combined with ulinastatin. The clinical curative effect, APACHEⅡscore and inflammatory factor were compared between the two groups. Results The effective rate was 96.00% in the observation group and 82.00% in the control group, and the effective rate in the observation group was significantly higher than that in the control group (P <0.05). The APACHEⅡ score in the observation group was significantly lower than that in the control group (P <0.05). The inflammatory factors IL-6, TNF-a and PCT in the observation group were better than those in the control group, the difference was statistically significant (P <0.05). Conclusion Ulinastatin combined with Xuebijing in treating septic sepsis complicated with septic shock has obvious clinical effect, reducing APACHEⅡscore, regulating inflammatory cytokines in vivo and alleviating patients’ pain, so it is worth further clinical application.